The medication Lenvanix 4 mg , with its generic name Lenvatinib, is a comprehensive therapy option designed to target various cancers through its action as a multikinase inhibitor. By targeting and inhibiting the vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), Lenvatinib effectively disrupts the vascular pathways that tumors utilize for growth and spread, making it a potent option for cancer treatment. Here’s a detailed breakdown of its features, indications, and storage conditions:

Product Overview

–Categories:

Classified under Anti-viral and Biotech Products, it is primarily noted for its application in treating Hepatitis in addition to its oncological uses.
-Manufacturer:** Produced by Beacon Pharmaceuticals Ltd., a notable entity in the pharmaceutical landscape, known for manufacturing advanced therapeutic drugs.

Indications and Uses

Lenvatinib serves as a frontline and subsequent therapy in various cancer treatments due to its mechanism of action:

1. Differentiated Thyroid Cancer (DTC): It’s indicated for patients with locally recurrent or metastatic, progressive, DTC that no longer responds to radioactive iodine treatment. By targeting the growth pathways, it aims to inhibit the proliferation of cancer cells.

2. Renal Cell Carcinoma (RCC):In combination with everolimus, Lenvatinib is prescribed for advanced RCC patients who have previously undergone one antiangiogenic therapy. This combination has shown to improve outcomes by further disrupting the tumor’s ability to grow and spread.

3. Hepatocellular Carcinoma (HCC):As a first-line treatment option, it offers new hope for patients with unresectable HCC, providing an alternative when surgical options are not viable due to the cancer’s advanced stage or location.

Storage Conditions

Temperature: Lenvanix 4 mg  should be stored at a controlled room temperature of 25°C (77°F), with allowable excursions to temperatures ranging from 15°C to 30°C (59°F to 86°F). This ensures the medication maintains its efficacy and safety for consumption.

The development and approval of Lenvanix 4 mg , particularly for conditions like unresectable HCC, mark a significant advancement in oncological care, offering patients and healthcare providers a new avenue for treatment with a targeted approach against cancer growth and spread.